2016 Zika virus epidemic

2016 Zika virus epidemic
Name	2016 Zika virus epidemic
Date	2015–2016
Location	Brazil, Caribbean, United States, Central America, South America
Cause	Zika virus
Deaths	Unknown
Confirmed cases	Hundreds of thousands (est.)

Contents

2016 Zika virus epidemic The 2016 Zika virus epidemic was a large-scale outbreak of Zika virus infection that emerged in Brazil and spread across the Americas, prompting international concern from World Health Organization, Pan American Health Organization, Centers for Disease Control and Prevention, United Nations, and national public health agencies. The epidemic coincided with major events such as the 2016 Summer Olympics in Rio de Janeiro and generated policy responses from heads of state including leaders from United States, Brazil, Colombia, Argentina, and Mexico. International scientific collaboration among institutions like Oswaldo Cruz Foundation, Institute Pasteur, University of São Paulo, Johns Hopkins University, and Centers for Disease Control and Prevention accelerated research into transmission, pathology, diagnostics, and vaccines.

Background

The epidemic arose after the identification of Zika virus in urban settings following prior detections in Micronesia and French Polynesia, with ecological context involving vectors such as Aedes aegypti and Aedes albopictus identified by entomologists at London School of Hygiene & Tropical Medicine and Oswaldo Cruz Foundation. Historical precedent included outbreaks linked to Yap Island and French Polynesia, and the virology was informed by work at Walter Reed Army Institute of Research and Institute Pasteur. Regional public health infrastructure in countries like Brazil, Colombia, Venezuela, and Honduras influenced surveillance capacity, while international bodies including World Health Organization and Pan American Health Organization coordinated guidance and risk assessment.

Reports of increased congenital malformations and clusters of rash illness in Northeast Brazil and cities such as Recife, Salvador, and Rio de Janeiro led to accelerated case finding in 2015 and 2016, with case confirmation by laboratories including Oswaldo Cruz Foundation, Institute Pasteur, and Centers for Disease Control and Prevention. By early 2016 the outbreak had spread through the Caribbean to islands like Puerto Rico, Dominican Republic, and Jamaica, and into continental Central America affecting El Salvador, Guatemala, and Honduras. The continental expansion reached United States territories and states including Florida and Texas, while autochthonous transmission was documented in Mexico and Panama and cases were reported in Argentina and Chile among travelers. Global travel hubs such as Miami International Airport, Jorge Chávez International Airport, and São Paulo–Guarulhos International Airport facilitated international dissemination and triggered alerts from World Health Organization and Centers for Disease Control and Prevention.

Transmission evidence combined vectorborne transmission by Aedes aegypti and less commonly Aedes albopictus with nonvector routes including sexual transmission documented in clinical reports involving patients followed by teams at Centers for Disease Control and Prevention and Johns Hopkins University. Clinical descriptions published by investigators at Oswaldo Cruz Foundation, University of São Paulo, and Institute Pasteur emphasized mild febrile illness with rash, conjunctivitis, and arthralgia, while severe outcomes such as Guillain–Barré syndrome were reported in surveillance data from Brazil, Colombia, and French Polynesia and studied by neurologists at Mayo Clinic and Johns Hopkins University. Laboratory confirmation employed RT-PCR and serology techniques refined by research groups at Centers for Disease Control and Prevention, Institute Pasteur, and Oswaldo Cruz Foundation, complicated by cross-reactivity with dengue virus and coinfections involving Chikungunya virus.

National responses included vector control campaigns led by ministries of health in Brazil, Colombia, and Puerto Rico deploying insecticide spraying, source reduction, and community mobilization supported by NGOs such as Doctors Without Borders and research partnerships with University of São Paulo and Oswaldo Cruz Foundation. International coordination by World Health Organization and Pan American Health Organization issued travel advisories and clinical guidance, while Centers for Disease Control and Prevention activated emergency operations centers and issued recommendations for blood donation screening and sexual transmission prevention. Policy actions involved collaboration with municipal governments in Rio de Janeiro and Miami-Dade County, engagement with international events like the 2016 Summer Olympics, and legal and ethical debates in legislatures of Brazil, United States Congress, and national health ministries regarding reproductive health counseling and contraception access.

Epidemiological and clinical studies from Brazil, Colombia, and Puerto Rico linked maternal infection with adverse outcomes including microcephaly and other congenital Zika syndrome features studied by pediatric teams at Hospital da Mulher do Recife, Boston Children's Hospital, and University of California, San Francisco. Obstetric guidelines issued by professional bodies such as American College of Obstetricians and Gynecologists, Brazilian Ministry of Health, and World Health Organization recommended screening, ultrasound surveillance, and counseling; these intersected with legal frameworks and debates in courts and legislatures in Brazil and El Salvador over reproductive rights. Public health policy adaptations included enhanced birth defect surveillance by agencies like Centers for Disease Control and Prevention and Pan American Health Organization, allocation of emergency funding by governments of United States, Brazil, and donors coordinated through World Health Organization and United Nations Children's Fund.

Research consortia involving National Institutes of Health, Wellcome Trust, Bill & Melinda Gates Foundation, Oswaldo Cruz Foundation, Institute Pasteur, and academic centers including Johns Hopkins University, University of São Paulo, and University of Oxford accelerated basic science on Zika virus structure and pathogenesis, leading to multiple vaccine candidates trialed by entities such as National Institutes of Health and biotech firms in early-phase trials. Diagnostic innovation included nucleic acid amplification tests developed by Centers for Disease Control and Prevention and serologic assays refined to reduce cross-reactivity with dengue virus by teams at Institute Pasteur and Oswaldo Cruz Foundation. Vector control research explored genetic approaches exemplified by programs from Oxitec and ecological studies by researchers at London School of Hygiene & Tropical Medicine, while international funders including Wellcome Trust and Bill & Melinda Gates Foundation supported operational research, clinical trials, and implementation science.

Category:Zika virus outbreaks